What is the current status of thrombolysis for acute ischemic stroke after 4.5 hours from symptom onset?

Thrombolysis After 4.5 Hours: Extended Window Treatment Now Supported

Intravenous thrombolysis beyond 4.5 hours is now evidence-based for appropriately selected patients with salvageable brain tissue identified by advanced imaging, extending the treatment window up to 24 hours from symptom onset.

Current Guideline Framework (Baseline Standard)

The 2018 AHA/ASA guidelines establish IV alteplase within 3-4.5 hours as Class I recommendation 1. However, these guidelines explicitly contraindicate treatment beyond 4.5 hours for patients with unclear or unwitnessed symptom onset 1. This represents the established standard but has been superseded by recent high-quality evidence.

Breakthrough Evidence: The Extended Window

The HOPE Trial Changes Practice (2025)

The most recent and highest-quality evidence comes from the HOPE randomized clinical trial 2, which definitively demonstrates:

• 372 patients treated 4.5-24 hours after onset with perfusion imaging selection
• Primary outcome achieved: 40% functional independence (mRS 0-1) with alteplase vs 26% with standard care (adjusted RR 1.52,95% CI 1.14-2.02, p=0.004)
• Absolute benefit: 14% increase in excellent outcomes
• Safety trade-off: 3.8% symptomatic ICH with alteplase vs 0.5% control (adjusted RR 7.34, p=0.01)
• Mortality unchanged: 11% in both groups

This trial provides Level A evidence that imaging-selected patients benefit from thrombolysis in the extended window despite increased hemorrhagic risk.

Supporting Meta-Analyses Confirm the Signal

Two 2025-2026 meta-analyses reinforce these findings:

The 2025 meta-analysis of 8 RCTs (1,742 patients) 3 demonstrated:

• Excellent outcomes: OR 1.43 (95% CI 1.17-1.75)
• Good outcomes: OR 1.36 (95% CI 1.12-1.66)
• Symptomatic ICH: OR 4.25 (95% CI 1.67-10.84)
• Number needed to treat: 12-16 for favorable outcome
• Number needed to harm: 62 for symptomatic ICH

The 2026 meta-analysis of 14 RCTs (4,174 patients) 4 corroborated:

• Excellent outcomes: RR 1.22 (95% CI 1.14-1.31)
• Good outcomes: RR 1.12 (95% CI 1.06-1.18)
• Symptomatic ICH: RR 2.44 (95% CI 1.45-4.09)
• Mortality: No significant difference (RR 1.13,95% CI 0.93-1.38)

Patient Selection Algorithm for Extended Window (4.5-24 Hours)

Mandatory Criteria:

1. Advanced imaging demonstrating salvageable tissue

   • Perfusion imaging (CT or MRI perfusion) showing penumbra
   • OR DWI-FLAIR mismatch on MRI
   • Perfusion imaging appears numerically superior (OR 1.45 vs 1.34 for DWI-FLAIR) 3

2. Time window: 4.5-24 hours from symptom onset or last known well

3. No initial plan for mechanical thrombectomy (these patients were excluded from trials)

4. Standard alteplase eligibility criteria otherwise met (blood pressure <185/110 mmHg, no recent surgery, etc.)

Special Populations:

Posterior circulation strokes: Real-world data from 3,508 patients 5 shows comparable safety and efficacy in the extended window, particularly for:

• Baseline NIHSS ≤5
• No large vessel occlusion
• Standard time window shows better outcomes only for NIHSS >5 or LVO present

Critical Safety Considerations

The Hemorrhagic Risk Trade-Off

You must counsel patients/families that symptomatic ICH risk increases 2.4-7.3 fold 4, 3, 2. However:

• Absolute risk remains relatively low (3-4% vs 0.5-1%)
• Mortality does not increase significantly
• Functional benefit substantially outweighs hemorrhagic risk (NNT 12-16 vs NNH 62)

Time Remains Critical Even in Extended Window

Real-world Chinese data 6 shows that even within the extended window:

• 48.4% treated at 4.5-<6 hours
• Only 21.3% treated at 12-24 hours
• Each 30-minute delay reduces functional independence probability by 2.6% within standard window 5

Treat as early as possible even when treating late.

Common Pitfalls to Avoid

1. Not obtaining perfusion imaging: This is the key selection tool. Standard CT alone is insufficient for extended window decisions.

2. Misinterpreting early ischemic signs as established infarction: Real-world data 7 shows 41.2% of "demarcated infarctions" were actually early ischemic signs—these patients may still benefit.

3. Automatically excluding patients on DOACs: This remains a barrier 7, but specific anti-factor Xa activity testing can guide decisions (though not specifically addressed in extended window trials).

4. Assuming mild symptoms preclude treatment: While mild symptoms (NIHSS <5) were the most common reason for withholding IVT 7, extended window trials included various severity levels.

Practical Implementation

For patients presenting 4.5-24 hours after onset:

1. Obtain CT or MRI perfusion imaging immediately (not just non-contrast CT)
2. Identify salvageable penumbra on perfusion maps
3. Verify standard alteplase contraindications are absent
4. Administer standard dose alteplase 0.9 mg/kg (max 90 mg) if imaging shows salvageable tissue
5. Monitor intensively for hemorrhagic complications in first 36 hours

The evidence strongly supports extending thrombolysis beyond 4.5 hours when imaging demonstrates salvageable brain tissue, fundamentally changing the "time is brain" paradigm to "tissue is brain."